'Huge Step Forward' in Advanced Ovarian Cancer

Adding both durvalumab and olaparib to standard-of-care treatment in newly diagnosed non-BRCA mutated advanced ovarian cancer represents a 'huge step forward,' says one expert.

Related Keywords

Chicago ,Illinois ,United States ,University Of Florida ,Florida ,Gainesville ,New York ,American ,Jennifer Markham ,Carol Aghajanian ,Foundation Inc ,Astrazeneca ,Drug Administration ,American Society Of Clinical Oncology ,Genetic Laboratories Inc ,Zai Lab ,Glaxosmithkline ,University Of Florida Health ,European Network Of Gynaecological Oncological Trial Groups ,Gynecologic Medical Oncology Service ,Memorial Sloan Kettering Cancer Center ,New York City ,American Society ,Clinical Oncology ,Merry Jennifer Markham ,Florida Health ,Medscape Medical News ,European Network ,Gynaecological Oncological Trial Groups ,Myriad Genetic Laboratories ,Clovis Oncology ,Repare Therapeutics ,Ovarian Cancer ,Alignant Ovarian Neoplasm ,Biologic Therapy ,Combination Chemotherapy ,Combination Drug Therapy ,Rug Therapy Combination ,Breast Cancer ,Alignant Breast Neoplasm ,Antiangiogenesis ,Angiogenesis Inhibitor ,Evacizumab ,Nhibitor Angiogenesis ,Cancer ,Alignant Neoplasia ,Arcinoma ,Humanized Monoclonal Antibody ,Rastuzumab ,Genomics ,Genomic Medicine ,Edicine Genomic ,